BIOMOTION SCIENCES WARRANT
NASDAQ: SLXNW (Biomotion Sciences Warrant)
Last update: 1 hour ago0.030
-0.02 (-35.48%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Biomotion Sciences Warrant | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 1.00 |
|
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Security Benefit Life Insurance Co /Ks/ | 30 Jun 2026 | 150,000 |
| Kepos Capital Lp | 31 Mar 2026 | 100,000 |
| Gabelli & Co Investment Advisers, Inc. | 31 Mar 2026 | 38,150 |
| Dupont Capital Management Corp | 31 Mar 2026 | 32,500 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |